NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)

November 7, 2018

Includes Data from More than Twenty-Five Studies, Including Six Using GeoMx Digital Spatial Profiler

SEATTLE, Nov. 07, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in understanding of immune response and cancer immunotherapy using the nCounter® and GeoMx™ platforms that will be presented at the 33nd Annual Meeting of the Society of Immunotherapy for Cancer (SITC).

"We are thrilled to see a number of high-profile abstracts that include data from our GeoMx Digital Spatial Profiler at the 2018 SITC conference," said Brad Gray, president and chief executive officer of NanoString. "The ability to quantify high-plex protein and RNA simultaneously can be a powerful tool for identifying and validating biomarkers, especially for applications in immuno-oncology."

More than 25 abstracts using NanoString's nCounter platform will be presented at the SITC Annual Meeting, being held at the Walter E. Washington Convention Center in Washington, D.C., Nov. 7-11, 2018. The research being presented spans a wide breadth of applications, including biomarker development, the study of immune responsiveness and resistance, and digital pathology.

Six studies included the use of NanoString's GeoMx Digital Spatial Profiler (DSP) platform in immuno-oncology research. These abstracts include numbers 031, P113, P131, P389, P428 and P429 that are included in the table below. DSP allows for digital quantification of protein and gene expression from discrete regions of FFPE tissue in an automated and multiplex format. DSP is expected to be commercially available with the launch of a new instrument planned for mid-2019, and is currently accessible through the company's Technology Access Program (TAP). NanoString is currently accepting applications for the TAP for its DSP technology at TAP@Nanostring.com.

Each year, SITC recognizes publications that demonstrated excellence in scientific research with its Journal for ImmunoTherapy of Cancer (JITC) best paper awards. The 2018 JITC "Best Basic Science Paper" was awarded for "Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)," to a team led by NanoString researchers that included, Patrick Danaher, Ph.D., Sarah Warren, Ph.D., Rongze Lu, Ph.D., Josue Samayoa, Ph.D., Amy Sullivan, B.S., Irena Pekker, Ph.D., Brett Wallden, M.S., Francesco M. Marincola, M.D., and Alessandra Cesano, M.D., Ph.D.

NanoString will host a Key Opinion Leader Dinner for Digital Spatial Profiling on the evening of Thursday, Nov. 8th. The dinner features presentations by leading academic and biopharma researchers on the use of nCounter gene expression and GeoMx Digital Spatial Profiling technologies to discover biomarkers for treating bladder cancer and melanoma.

At the 2018 SITC Annual Meeting, NanoString will showcase its nCounter platform, IO360 and Data Analysis and Digital Spatial Profiling at booth #600.

Abstract #	Title	Presenting Author
O31	Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma	David Page, MD Providence Portland Cancer Center, Portland, OR, USA
O45	Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444	Lawrence Fong, MD University of California, San Francisco, CA, USA
P25	Consistent pharmacodynamics and immunological responses to the TLR9 agonist, SD-101, following intratumoral injection in multiple cancer types	Albert Candia, PhD Dynavax Technologies, Berkeley, CA, USA
P35	Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928	Daniel DiRenzo, PhD Arcus Biosciences, Hayward, CA, USA
P43	The presence of exhausted CD8+ T cells identifies a subset of immunogenic ER+ breast cancer patient tumors	Colt Egelston, PhD Beckman Research Institute, City of Hope, Duarte, CA, USA
P53	X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor inflammatory status in the microenvironment of melanoma	Robert Andtbacka, MD Huntsman Cancer Institute, Salt Lake City, UT, USA
P54	Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444	Andrew Hotson, PhD Corvus Pharmaceuticals, Burlingame, CA, USA
P67	Innovative combinatorial approach to characterize the immune landscape and analyze the tumor response after anti-PD-1 blockade in a 3D ex-vivo tumoroid system of non-small cell lung cancer	Melba Marie Page, PhD Nilogen Oncosystems, Tampa, FL, USA

P87	Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial	Luc R. Desnoyers, PhD CytomX Therapeutics, Inc., South San Francisco, CA, USA
P113	Digital spatial profiling of bone-marrow infiltrating immune cells in acute myeloid leukemia	Sergio Rutella, MD, PhD Nottingham Trent University, Nottingham, UK
P131	High-plex predictive marker discovery for melanoma immunotherapy treated patients using NanoString® Digital Spatial Profiling	David Rimm, MD, PhD Yale University School of Medicine, New Haven, CT, USA
P136	Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab	Breelyn Wilky, MD University of Miami - SCCC, Miami, FL, USA
P139	"Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of T-cell	Funda Meric-Bernstam, MD MD Anderson Cancer Center, Houston, USA
P327	Higher dose single-agent intratumoral G100 (a TLR4 agonist) results in increased biomarker activity and improved clinical outcomes in patients with follicular lymphoma	Ahmad Halwani, MD Huntsman Cancer Institute, Salt Lake City, UT, USA
P349	Spatial distribution analysis reveals increased PD1 expression on cytotoxic T cells leading to tumor regression upon combined MEK and HDAC inhibition in spontaneous PDAC mouse model	Phyllis Cheung, PhD University Hospital Essen, DKFZ, Essen, Germany
P354	Co-clinical trials of MEK inhibitor, anti PD-L1 and anti CTLA-4 combination treatment in Non-Small Cell Lung Cancer	Pierre-Olivier Gaudreau MD Anderson Cancer Center, Houston, USA
P360	Enhanced anti-tumor efficacy of mesothelin-targeted immunotoxin LMB-100 combined with anti-PD-1 antibody	Qun Jiang, PhD National Institutes of Health, Bethesda, MD, USA
P389	Digital spatial profiling on uveal melanoma tissue treated with combined radiofrequency ablation and ipilimumab	Trieu My Van, PhD NKI/Nanostring, Amsterdam, Netherlands
P428	Spatially-resolved, high-plex digital profiling enables characterization of complex immune biology of the colorectal cancer microenvironment	Sarah Church, PhD NanoString Technologies, Seattle, WA, USA
P429	Integrative spatially-resolved, high-plex digital profiling enables characterization of complex immune biology in the tumor microenvironment of mesothelioma	Carmen Ballesteros Merino, PhD, Providence Portland Cancer Center, Portland, OR, USA
P450	The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models	Luis Carvajal, PhD Aileron Therapeutics, Inc., Cambridge, MA, USA
P460	Chemotherapy induced immunogenic cell death and response to STING agonist in high-grade serous ovarian cancer	Sarah Nersesian, MSc Queen's University, Kingston, ON, Canada
P468	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod	Mariya Rozenblit, MD Yale University, Connecticut, CT, USA
P564	Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis	Daniel Johnson, MD MD Anderson Cancer Center, Houston, TX, USA
P597	Reovirus infection of prostate cancer induces upregulation of the negative regulators PD-L1 and BTLA	Nicola Annels, PhD The University of Surrey, Guildford, UK
P614	Nano-Pulse Stimulation™ of murine melanoma and mammary carcinoma is a physical modality that eliminates the treated tumor by regulated cell death and induces innate and adaptive immune responses	Amanda McDaniel, BA Pulse Biosciences, Burlingame, CA, USA
P650	Selective CD47 immune checkpoint targeting on tumor cells modulates the tumor microenvironment to enhance macrophage tumoricidal function	Vanessa Buatois, PhD Novimmune SA, Geneva, Switzerland

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the capabilities of the company's current and future products and the timing of future product launches. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; the impact of competition; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

Contact:

Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

Source: NanoString Technologies, Inc.